Clinical Trial Update: Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating intravenous efzofitimod for pulmonary sarcoidosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Sarcoidosis

Drugs mentioned

• Efzofitimod (efzofitimod)

Snippet

Sponsor: aTyr Pharma, Inc. | Conditions: Pulmonary Sarcoidosis | Phase 3 | Status: COMPLETED